Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director | June 11, 2026 | June 16, 2026 |
| OmniAb, Inc.AHPA · Entity 5294 | Director | August 09, 2021 | August 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date June 11, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.59 · Expires 2036-06-11 | Direct | 199,246 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 40,565 · Balance 199,246 |
OmniAb, Inc.
Report date August 09, 2021 · Filed August 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary Shares, par value $0.0001SEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-08-09 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person owns 35,000 Class B Ordinary Shares which are convertible into Class A Ordinary Shares as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-257177). The Class B Ordinary Shares have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person owns 35,000 Class B Ordinary Shares which are convertible into Class A Ordinary Shares as described under the heading "Description of Securities-Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-257177). The Class B Ordinary Shares have no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CombiMatrix Corp
Report date November 14, 2017 · Filed November 16, 2017
Section 16 reporting ended · disclosed 2017-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-11-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-11-14 · Disposition to issuer · Disposed 835 · Balance 7,792 F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 725 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Row 2 · 2017-11-14 · Other · Disposed 7,792 · Balance 0 F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 6,772 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 725 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 6,772 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 16, 2026 01:30 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001635493-26-000002 · ownership.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,246 Underlying: Common Stock · 40,565 shares Expires 2036-06-11 Read SEC document |
| June 26, 2025 Filed Jun 27, 2025 23:40 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 40,565 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001641172-25-016989 · ownership.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,681 Underlying: Common Stock · 40,565 shares Expires 2035-06-26 Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 20:09 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 29,700 | $0.00 Strike: $2.33 | $0.00 |
DisclosureSEC source: 0001628280-24-030643 · wk-form4_1719864565.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,974 Underlying: Common Stock · 29,700 shares Expires 2034-06-27 Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 21:05 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 27,700 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001628280-23-022736 · wk-form4_1687295135.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,274 Underlying: Common Stock · 27,700 shares Expires 2033-06-15 Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 22:08 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 15,000 | $1.64 | $24,525.00 |
DisclosureSEC source: 0001628280-22-025265 · wf-form4_166371172268717.xml · nonDerivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 113,788 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.625 to $1.64. Full information regarding the number of shares purcahsed at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 20:10 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | Exercise / conversionStock Options · Derivative | 28,858 | $2.60 Strike: $2.60 | $75,030.80 |
DisclosureSEC source: 0001628280-22-018607 · wf-form4_165713821643094.xml · derivative · entry 2 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,716 Underlying: Common Stock · 28,858 shares Expires 2030-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 20:10 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | Exercise / conversionCommon Stock | 28,858 | $2.60 | $75,030.80 |
DisclosureSEC source: 0001628280-22-018607 · wf-form4_165713821643094.xml · nonDerivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 98,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2022 Filed Mar 10, 2022 23:43 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 26,800 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001628280-22-005797 · wf-form4_164695579568634.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,574 Underlying: Common Stock · 26,800 shares Expires 2032-03-09 Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:14 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 22,000 | $0.00 Strike: $7.98 | $0.00 |
DisclosureSEC source: 0001628280-21-012178 · wf-form4_162370162899357.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,774 Underlying: Common Stock · 22,000 shares Expires 2031-06-10 Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:16 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 28,858 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-20-075240 · a4.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,774 Underlying: Common Stock · 28,858 shares Expires 2030-06-17 Read SEC document |
| May 14, 2020 Filed May 18, 2020 20:16 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 69,930 | $1.43 | $99,999.90 |
DisclosureSEC source: 0001104659-20-063176 · a4.xml · nonDerivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 69,930 Read SEC document |
| April 16, 2020 Filed May 1, 2020 20:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 11,916 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001104659-20-055489 · a4.xml · derivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 11,916 shares Expires 2030-04-16 F1 · derivative.exercise_date: 3,972 of the Stock Options vest on each of 4/16/2021, 2022 and 2023 Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 17:55 UTC | CombiMatrix Corp CBMX · Entity 171845 | OtherCommon Stock | 7,792 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-014228 · edgar.xml · nonDerivative · entry 2 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 6,772 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 17:55 UTC | CombiMatrix Corp CBMX · Entity 171845 | Disposition to issuerCommon Stock | 835 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-014228 · edgar.xml · nonDerivative · entry 1 White Lale · CIK 0001635493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,792 F1 · price: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 725 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.